Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -9 of 9
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab in MALT Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
IELSG19
NCT00210353
Last Modified:
1/25/2008
First Published:
12/20/2007
2.
Phase III Randomized Study of First-Line Therapy Comprising Chlorambucil Versus Fludarabine Phosphate in Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma With Villous Lymphocytes, or Non-IgM Lymphoplasmacytic Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
TSH-WM1
ISRCTN56052618, TSH-WM1, NCT00608374
3.
Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
WM1
NCT00566332
4.
Ofatumumab-Chlorambucil Combination vs. Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Approved-not yet active
18 and over
Pharmaceutical / Industry
OMB110911
EudraCT 2008-004932-19, NCT00748189
5.
Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
CR0506PI
REC:05-054, NCT00558961
6.
Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
INST 1003C
NCT00250718
7.
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
MO20927
NCT00532129
First Published:
8/21/2008
8.
Phase II Study of Rituximab, Bortezomib, Doxorubicin Hydrochloride, Dexamethasone, and Chlorambucil as First-Line Therapy in Older Patients With Stage II-IV Mantle Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
65 to 80
Other
GOELAMS-MANTEAU-2006-SA
MANTEAU 2006 SA, EUDRACT-2006-004768-30, INCA-RECF0475, NCT00740415
9.
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Approved-not yet active
60 and over
Pharmaceutical / Industry
ML21445
2008-001612-20, NCT00738374
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
